Metraipolis › archive › dc_97dcb876a394
Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration — Europe PMC PMID:41976308
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41976308
- DOI
- 10.3390/cancers18071085
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T20:50:06.150Z
- SHA-256 of the archived text
ae4d0ea6f241c04f3923616eb5f7d8e3cb6237bd4ea126a2bea7c39c1f754d6b- Stable URL of this page
https://metraipolis.com/documento/dc_97dcb876a394
How to cite
Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration — Europe PMC PMID:41976308 — Europe PMC (en), https://europepmc.org/article/MED/41976308 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_97dcb876a394 (Metraipolis archive dc_97dcb876a394, sha256 ae4d0ea6f241c04f3923616eb5f7d8e3cb6237bd4ea126a2bea7c39c1f754d6b)
BibTeX
@misc{dc97dcb876a394,
title = {Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration — Europe PMC PMID:41976308},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41976308},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_97dcb876a394; sha256 ae4d0ea6f241c04f3923616eb5f7d8e3cb6237bd4ea126a2bea7c39c1f754d6b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41976308. Agents can read the archived copy with the MCP tool read_document.